ITERUM THERAPEUTICS PLC (ITRM) Stock Price & Overview
NASDAQ:ITRM • IE000TTOOBX0
Current stock price
The current stock price of ITRM is 0.03 USD. Today ITRM is down by -57.39%. In the past month the price decreased by -80.03%. In the past year, price decreased by -97.35%.
ITRM Key Statistics
- Market Cap
- 1.599M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.73
- Dividend Yield
- N/A
ITRM Stock Performance
ITRM Stock Chart
ITRM Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ITRM. When comparing the yearly performance of all stocks, ITRM is a bad performer in the overall market: 99.67% of all stocks are doing better.
ITRM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ITRM. ITRM may be in some trouble as it scores bad on both profitability and health.
ITRM Earnings
On March 12, 2026 ITRM reported an EPS of -0.2 and a revenue of 390.00K. The company missed EPS expectations (-78.25% surprise).
ITRM Forecast & Estimates
8 analysts have analysed ITRM and the average price target is 9.18 USD. This implies a price increase of 30500% is expected in the next year compared to the current price of 0.03.
ITRM Groups
Sector & Classification
ITRM Financial Highlights
Over the last trailing twelve months ITRM reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 63.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.95% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ITRM Ownership
ITRM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ITRM
Company Profile
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company is headquartered in Dublin, Dublin and currently employs 9 full-time employees. The company went IPO on 2018-05-25. The firm develops differentiated anti-infectives. The company offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The firm operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Company Info
IPO: 2018-05-25
ITERUM THERAPEUTICS PLC
3 Dublin Landings, North Wall Quay, Dublin 1
DUBLIN DUBLIN 2 IE
CEO: Corey N. Fishman
Employees: 9
Phone: 35319038354
ITERUM THERAPEUTICS PLC / ITRM FAQ
What does ITERUM THERAPEUTICS PLC do?
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company is headquartered in Dublin, Dublin and currently employs 9 full-time employees. The company went IPO on 2018-05-25. The firm develops differentiated anti-infectives. The company offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The firm operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
What is the current price of ITRM stock?
The current stock price of ITRM is 0.03 USD. The price decreased by -57.39% in the last trading session.
Does ITERUM THERAPEUTICS PLC pay dividends?
ITRM does not pay a dividend.
How is the ChartMill rating for ITERUM THERAPEUTICS PLC?
ITRM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How many employees does ITERUM THERAPEUTICS PLC have?
ITERUM THERAPEUTICS PLC (ITRM) currently has 9 employees.
What is ITERUM THERAPEUTICS PLC worth?
ITERUM THERAPEUTICS PLC (ITRM) has a market capitalization of 1.60M USD. This makes ITRM a Nano Cap stock.